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a b s t r a c t
Multiple sclerosis is a disease that still has not been fully understood and calls for better
diagnostic procedures for the improvement of everyday patient care and drug development.
Routine magnetic resonance examinations reveal demyelinating focal lesions, but they do
not correlate sufﬁciently with the patients' disability and cognitive impairment. For more
than 100 years it has been known that demyelination affects not only white but also grey
matter of the brain. Recent research has conﬁrmed the serious consequences of grey matter
pathology. Over the last several years, atrophy of the brain and especially of its grey matter
has become a most promising marker of the patients' clinical status. The paper discusses the
concept and importance of atrophy assessment in relation to the standard magnetic
resonance results.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Multiple sclerosis (MS) affects approximately 2.5 million
people worldwide. It is an acquired, chronic inﬂammatory
disease of the central nervous system (CNS) characterised by
the presence of inﬂammatory-demyelinating lesions and
progressive loss of brain tissue. The condition was ﬁrst
described over 170 years ago; however, its aetiology is still
unclear. Until the 1980s, that is, until partial efﬁcacy of* Corresponding author at: ul. Reta 39G, 43-190 Mikołów, Poland. Tel.: 
E-mail address: hartel@voxel.pl (M. Hartel).
http://dx.doi.org/10.1016/j.pjnns.2016.01.007
0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Simmunosuppressive drugs was demonstrated, MS was con-
sidered an incurable disease. Symptoms of MS include
progressive impairment of motor and sensory functions, as
well as cognitive disorders. The disease is the most common
non-traumatic cause of disability in young people [1,2].
Primary lesions in MS are believed to be of inﬂammatory
aetiology. However, due to gradual deterioration of the
patients' clinical condition and to lesions found in diagnostic
imaging, MS has recently been considered also a degenerative
disease. The primary pathological process in MS affects myelin+48 667 666 931; fax: +48 32 790 42 20.
p. z o.o. All rights reserved.
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brain components [3].
In a routine MRI scan, demyelinating lesions are usually
found in the white matter. However, since 1880s it has been
known from histopathological examinations that the patho-
logical process also takes place in the grey matter (GM) [4]. This
has been conﬁrmed by modern diagnostic imaging techniques,
and nowadays the classiﬁcation of MS as solely a white-matter
disease is increasingly regarded as obsolete [5].
2. Magnetic resonance imaging in MS
What can be visualised by routine MRI still remains ‘‘the tip of
the iceberg’’. The amount of lesions revealed, in most cases in
the white matter (WM) only, is quite small in comparison to
the known extent of CNS damage which remains beyond the
capabilities of the standard imaging sequences. This often
results in a discrepancy between the clinical symptoms and
the ﬁndings in routine MRI, i.e. the so-called clinical-
radiological paradox [11]. In the relapsing-remitting (RR) form,
MRI reveals 10–20 times more new lesions than the number of
known clinical relapses. In some patients, active lesions
remain visible in MRI for a very long time, and yet the clinical
course of the condition is stable. Half of untreated asymptom-
atic patients present active plaques in MRI [6].
Neuroradiological markers are constantly being sought that
would be more clearly correlated with the patient's condition
and would be more useful for effective modiﬁcation of
treatment. For this reason, attention has been paid to the
damage of normal-appearing white matter (NAWM) and
normal-appearing grey matter (NAGM). It is supposed that
these areas could be damaged as a result of Wallerian
degeneration of the ﬁbres passing through the plaques visible
in the MRI image, or due to an independent pathological
process. The progression of damage to the normal-appearing
brain tissue (NABT), resulting in increasing atrophy, is
associated with the progression of the patient's disability.
As there is no direct relationship between the clinical
symptoms and the number of plaques, it is the atrophy that
is considered to reﬂect MS pathology, being invisible in
conventionally assessed MR imaging [12].
Given that MR imaging went into clinical use in 1980, the
publication The evaluation of multiple sclerosis by magnetic
resonance imaging, Val M. Runge et al. is one of the ﬁrst to describe
the application of this method in MS. The today's standard MRI
scan protocol is not much different from that presented in the
article. Certainly present routine scans are of better quality and
are obtained in a shorter time, but they are still unable to show
CNS pathology located beyond demyelination lesions. With the
use of modern MRI scanners which allow to modify the
sequence in research mode, DIR (double inversion recovery)
sequences can be activated. Nevertheless, they remain imper-
fect, revealing up to 20% of GM lesions [13,14]. Only a few centres
are able to track the atrophy of the brain and its components, but
it is still not a standard procedure to use this information for the
purpose of therapy modiﬁcation.
Atrophy assessment predicts disease progression in the
years to come. MRI techniques permit the detection of
differences in brain volume in a relatively short period oftime – even within 6–12 months. That is why we need software
that could be used for daily diagnosis of patients, and not only
for research [6]. The increasingly available programmes are
relatively easy to use and will soon allow to include an
assessment of brain atrophy in multiple sclerosis patients in
routine MRI reports [15,16].
3. Grey matter pathology in MS
Basing on histopathological examinations, several types of
plaques in the cerebral cortex are distinguished: (1) located at
the border between the cortex and the white matter, (2) not
reaching the surface of the cerebral cortex, (3) located
externally, under the arachnoid (the most common ones).
Some authors distinguish type 4: lesions involving the entire
thickness of the cerebral cortex.
Microscopic examination has also demonstrated that
demyelination is often more pronounced in the grey matter
than in the white matter. Its presence correlates better with
the patient's clinical condition than the WM pathology but
routine MRI performed in MS does not show GM plaques well
enough. Grey matter damage involves diffuse and local
demyelination, and is often secondary to lesions in the white
matter. The percentage of inﬂammatory lesions in the GM is
lower and the process involves other inﬂammatory cells
besides WM. Also, partial BBB damage takes place [6].
Degenerative processes in the grey matter are not always
associated with demyelination, and the pathologies of the
white and grey matter are independent processes, at least to
some extent. However, 80% of lesions examined in microscopy
are not visible in the modern sequences (including DIR),
applied for visualisation of the grey matter pathology in MS.
This is particularly relevant for lesions located under the pia
mater. The number of demyelinating lesions in the grey matter
is clearly associated with the patient's disability progression
and the reduction of his/her intellectual abilities. Besides DIR
sequence, the use of diffusion tensor imaging (DTI) can also
help detect cortex damage. A decrease in fractional anisotropy
(FA) is associated with the plaques volume and worse patient's
clinical condition [7].
The grey matter represents 65% of the parenchymal brain
volume. Therefore, its atrophy clearly affects the volume of the
whole brain. GM atrophy correlates better with the patient's
clinical presentation than WM atrophy or the total plaque
volume [6,8].
The difﬁculty in observing grey matter pathology is due to
the fact that this process cannot be adequately shown in vivo
in routine MRI scans. The visualisation of demyelinating
lesions and GM atrophy with advanced MRI techniques could
not only supplement routine diagnostics but also allow to
better correlate imaging with the clinical status of patients. On
the other hand, it suggests that GM damage should be
considered as a target for modern MS therapies [9–11].
4. Brain atrophy and its assessment
Atrophy of the brain leading to an irreversible loss of its tissues
is a well-known phenomenon, directly related to the clinical
Fig. 1 – (a and b) Series of FLAIR images obtained from two 41-year-old female patients with RRMS: (a) EDSS score 2.0; (b) EDSS
score 4.0 with much more pronounced brain atrophy, dilated ventricles, widened grooves and fissures of the cerebral cortex.
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gradual widening of the paracerebral spaces, sulci, ﬁssures,
cisterns and ventricles of the brain. These changes occur much
faster in MS patients than in healthy subjects who present
physiological atrophy progressing with age. Loss of brain per
year in MS is up to 1.4% vs. 0.3% loss of brain in healthy
subjects; according to other authors, this percentage is 0.5–
1.0% vs. 0.1–0.3% in the normal population [17,18].
Compared with healthy subjects, MS patients have lower
white matter volume, and when assessed in a long term, the
grey matter is lost at a higher rate. At the beginning of this
century, thanks to immunohistochemical techniques showing
myelin, it was demonstrated that more than 66% of the GM is
involved in the disease process, and the pathology affects
mainly the basal ganglia [19,20].
Atrophy progresses throughout the continuum of the
disease, at any stage of MS and at a similar rate in various
forms of MS. Atrophy results not only from demyelination but
also from the loss of neurons. This process is secondary,
among other mechanisms, to the inﬂammatory process and
demyelination as well as Wallerian degeneration and im-
paired remyelination [17,18,21]. GM atrophy progresses at aclearly higher rate when the disease has advanced into the
secondary progressive form. Slow atrophy rate may suggest a
benign form of MS [22].
Axons represent 46%, and myelin 24% of the WM volume.
Even if remyelination occurs, the secondarily produced myelin
sheath has a smaller thickness/volume, and axonal loss is not
reversed. For this reason, atrophy is determined not so much
by the loss of myelin as by the loss of axons. Demyelination in
plaques constitutes 1% of total brain atrophy and even if a
plaque enlarges by approximately 10% per year, this repre-
sents only 0.1% of the total atrophy. It is believed that atrophy
means loss of axons and myelin not only in the demyelination
lesions but mainly in the normal-appearing brain tissue
(NABT).
Brain atrophy correlates with the patients' progressive
cognitive and physical impairment much better than an
evaluation of changes in T2-weighed images. Atrophy has
been found to be related to the number of depression episodes,
fatigue, and deterioration in the patients' quality of life [6]. An
assessment of atrophy in the ﬁrst two years of the disease
predicted the occurrence of cognitive impairment as early as
seven years after the diagnosis [23].
Fig. 2 – (a and c) 3D-T1 image postprocessing performed with SIENAX at the level of basal ganglia: (a) segmented grey matter,
(b) segmented white matter, (c) combined image (segmented grey + white matter).
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signiﬁcantly with the symptoms presented by MS patients – for
example, atrophy of the thalamus has an apparent relation to
cognitive impairment. Other authors emphasise the fact that
atrophy of the subcortical GM and the cerebral cortex is a better
marker than the observation of atrophy of the white matter or
the total brain volume, and it is visible from the very onset of
the disease.
The ﬁrst scientiﬁc papers on the issues of atrophy in MS
were published more than 15 years ago [22,24]. From the very
beginning, the authors were interested in the changes in brain
ventricular volume as indirect indications of the loss of brain
tissue. Changes in ventricular volume are mainly due to the
loss of subcortical grey matter – an enlargement of the lateral
ventricles does not correlate with the loss of the white matter
[25,26]. The enlargement of the ventricular system, i.e. central
atrophy, has a predictive value in the so-called mean follow-up
time (5 years from the baseline assessment). The correlation
with clinical symptoms is stronger than in the case of the total
plaque volume or total brain atrophy [27].
An objective method for measuring atrophy is relatively
easily accessible. The option of volumetric imaging using 3D-
T1 sequence is available in almost every MRI scanner. This
sequence is the basis which should be acquired in the best
possible resolution and image contrast.
The following techniques are used in the objective atrophy
assessment:
1. Manual methods like linear measurements and manual
outlining (width of the brain, corpus callosum, ventricles,
bicaudate ratio, volume calculated from outlining of the
brain on every slice or cerebrospinal ﬂuid (CSF) volumes. A
disadvantage of these methods is low repeatability and
precision of measurements; moreover, they are time-
consuming.
2. Semi-automated methods are faster and offer better
reproducibility – segmentation algorithms like seed grow-
ing, edge detection or contouring.
3. Automated segmentation – still less time-consuming and
more reproducible. Segmentation is possible thanks to thedifferences in signal intensity between the brain parenchy-
ma and CSF, GM and WM, as well as brain parenchyma and
MS lesions (brain parenchymal fraction – BPF, SIENAX, SPM,
FreeSurfer) (Fig. 2).
4. Registration and boundary-based methods, which reveal
the volume change by calculating the difference between
the scans of normal controls and those of the patients.
Comparison of subjects with different head size is possible
thanks to the use of volume normalisation and relative
values (SIENA, voxel-based morphometry – VBM) [21,28,29].
In a review article, Radü et al. classify all the above
techniques except VBM as whole brain volume methods. More
advanced techniques – VBM together with cortical thickness
(CT) – belong to the regional volume group [30].
VBM. 3D-T1 data can also be postprocessed with the use of
voxel-based morphometry (VBM). It is an automated tech-
nique detecting the subtle changes in brain tissue density at a
voxel level. Recently it has been increasingly used for
predominantly GM changes in MS. VBM provides statistical
analysis of the group differences thanks to spatially normal-
ised images. The result is a statistical parametric map showing
regions where GM concentration differs signiﬁcantly between
groups [31,32].
Cortical thickness assesses the cortical damage in MS by
measuring focal cortical thinning in addition to the analysis of
cortical volume. Cerebral cortex thinning is an earlier
pathological ﬁnding than tissue loss. It correlates with fatigue
and cognitive deﬁcits, which have recently been gaining
importance as clinical markers [33,34].
BPF is one of the most popular quantifying methods for
brain volume loss assessment used in clinical trials. The
estimation of brain parenchymal fraction, widely applied since
1980s, is deﬁned as the ratio of brain parenchymal volume to
the total brain volume (a sum of brain and ventricle CSF
volume). This technique is highly reproducible and takes into
account individual variability in head size between subjects
[35–38].
The described calculation methods can use data of 1.5–3 T
ﬁeld MRI. Thanks to the technology development a number of
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like 7–9.4 T. High signal-to-noise ratio and high-resolution
images permit improved visualisation of demyelination
lesions within GM. Better resolution also contributes to more
accurate assessment of the cortical volume and cortical
thickness [39–41].
Objective measurements can be incorporated into clinical
assessment, although this has not been included in the MS
treatment criteria. The accuracy of measurements performed
with automatic methods is very similar to that of semi-
automatic methods [47]. However, other authors have dem-
onstrated advantages of registration techniques in compari-
son to segmentation techniques. It is crucial that the follow-up
of atrophy in a given patient should take place invariably in the
same centre, with the same MRI scanner and the same
sequences and planes [48].
Since the loss of white matter depends, inter alia, on the
volume and activity of plaques, there are differences in
assessing atrophy of the grey and white matter. Active plaques
appear more frequently in the WM, and WM volume is affected
by gliosis and inﬂammation. This relationship is less marked
with atrophy of the grey matter. Therefore, GM assessment is
believed to be more reliable for the evaluation of brain atrophy
because it is less prone to errors [6].
In their study of 2012, Shiee et al. found no loss of white
matter volume in the initial stages of the disease. This
component of the brain is more susceptible to inﬂammation
than the grey matter, which affects, among other parameters,
the interference in WM volume measurements [6,49]. Hor-
akova et al. demonstrated analogous differences manifested
in less distinct loss of white matter as compared to grey matter
over a ﬁve-year follow-up period [50]. Similarly, according to
Raz et al., the damage to the WM could indeed be detected
early and have affected most of its ﬁbres. However, it did not
deteriorate during the ﬁrst year after the onset of symptoms.
There was a clear decrease in the volume of the cerebral cortex
and the subcortical GM in the ﬁrst year of the follow-up [51]. In
2006, Simon argued that in long-term observation there was
also an obvious loss of the white matter, although it was not as
marked as in the grey matter [17].
Of course, the absence of WM atrophy in the early stages of
MS may result from the coexistence of both damage and
repair processes [49]. Volumetric measurements of the brain
in MS patients are affected by many factors, such as the loss
of nerve cells, inﬂammation, microglia volume, ﬂuid shifts,
the physiological process of ageing, remyelination, gliosis
[17]. Interference may result from changes associated with
plaque (oedema/acute phase), introduction of steroid thera-
py, dialysis, medication effects, rapid dehydration or rehy-
dration, eating disorders, alcohol abuse. These factors should
be taken into account in the analysis of atrophy in MS
patients but in long-term follow-up their importance
decreases [6,52]. Most commonly, low hydration and effects
of therapy (anti-inﬂammatory or immunomodulatory drugs)
decrease brain volume in reversible manner due to the loss of
water during dehydration and reduction of oedema/inﬂam-
mation. This phenomenon, called pseudoatrophy, represents
loss of water without actual brain damage. GM volume is less
affected by pseudoatrophy than the whole brain or WM
volume [17,42–44].The reduction of cerebral cortex thickness, which is already
visible at the onset of MS symptoms, was one of the ﬁrst
measurements in the research of GM atrophy [53,54]. Many
studies have consistently proved that grey matter atrophy
dominates from the earliest periods of the disease in various
forms of MS, and it is evident even with few plaques in the GM.
According to a newer hypothesis, cortical pathology is present
from the early stages of MS and is independent from the
ongoing pathological process in the white matter [1,13].
Many authors have emphasised the early occurrence of GM
and cerebral cortex atrophy. Zivadinov – the ﬁrst ﬁve years of the
disease, Shiee – one-year follow-up in patients with a mean time
of eight years from MS diagnosis, and Geurts – the earliest signs
of atrophy in MS appearing in the thalamus [49,55,56].
According to Popescu et al., measurements of brain atrophy
between the baseline assessment and the follow-up after 1–2
years have a predictive value for disability. They correlate with
a decline in the patient's EDSS scores after 10 years. Atrophy is
associated with short- and medium-term progression of the
clinical status, and the parameters of the whole brain atrophy
and central atrophy displayed the highest correlation in the
entire study population [57].
With technological advances in the software used for
measuring atrophy, it has become possible to determine the
volume of ever smaller substructures of the brain. According to
Zivadinov, the earliest damage in patients with CIS in the grey
matter occurs in the thalamus, and the progression of atrophy
in this structure allows to predict the transition to clinically
deﬁnite MS (CDMS) [37].
Atrophy of the GM, cortex, thalamus and subcortical GM is
visible at a very early stage of MS. The ﬁrst two components
evolve over 10 years, correlating with EDSS scores; they have a
predictive potential for the patient's symptoms [58,59]. These
results were conﬁrmed by Bertrand – atrophy of the thalamus,
and not the cortical structures, was signiﬁcant in patients with
the RR form over the ﬁrst 4 years of the disease. According to
Sicotte, hippocampal atrophy correlates with neuropsycho-
logical cognitive tests and lexical memory [60,61]. Differences
in the corpus callosum atrophy are also characteristic of
subtypes of MS, but there is no such relationship in the other
parts of the brain [62]. In addition, Kalincik reported being able
to predict the evolution of CDMS in patients with a higher
degree of atrophy, increased local inﬂammatory activity and
atrophy of the corpus callosum in a short six-month analysis
of studies [63].
Predictive value was also discovered in patients with the
PPMS form: grey matter atrophy in the early stages of the
disease correlated with MS progression observed as early as
after 5 years [64]. Furthermore, the atrophy of the substruc-
tures has been increasingly clearly associated with more
precise clinical data, such as the results of neuropsychological
tests [65,66].
For these reasons, it seems that in the near future the
development of techniques used for practical measuring of
atrophy in daily radiological practice should offer wider
opportunities than the calculation of the total brain volume.
Atrophy of the brain's main components, such as cerebral
cortex, GM or WM, as well as the substructures of the grey or
white matter such as the thalamus or the corpus callosum
seem to be the desired targets.
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for atrophy measurements, there are also other MRI techni-
ques. However, they are less practical for including into
everyday MRI protocol. They reﬂect the damage of the NABT,
which correlates with the clinical condition of MS patients as
well as the brain atrophy. Recently they have also found
application, with particular reference to GM.
Magnetisation transfer (MT) concept is based on the
mechanism of magnetisation exchange between freely mobile
protons (interstitial ﬂuid water) interacting with a pool of
restricted protons, bounded with macromolecules (like myelin
and brain tissue lipids). The differences in proton mobility
create different reaction to the radio wave of MRI scanner.
After saturating pulse macromolecular protons transfer part of
the saturation onto the free water protons. The transfer can be
quantiﬁed as a calculation of magnetisation transfer ratio
(MTR). During the course of the disease after demyelination
and axonal damage the amount of restricted proton is reduced.
Because of that the possibility of magnetisation transfer is
reduced (low MTR) as compared to normal controls (high MTR).
MTR reduction is related to the deterioration of the patient's
clinical condition.
Diffusion weighted imaging (DWI) and diffusion tensor
imaging (DTI). DWI enables the measurement of water
molecule mobility, which is reduced in the brain by tissue
and cellular structures. Due to pathological processes the
mobility can increase or decrease, which can be characterised
and quantiﬁed by the apparent diffusion coefﬁcient (ADC).
DWI reﬂects isotropic diffusion – without taking into consid-
eration the spatial orientation of tissue barriers. Since water
molecule mobility is not the same in all directions, a more
advanced technique (DTI) is used to characterise anisotropic
diffusion (including the factor of tissue barrier orientation).
DTI reveals the preferred water diffusion along nerve ﬁbres. In
the damaged NAWM of MS patients ADC rises. DTI is
characterised by fractional anisotropy (FA) and mean diffusiv-
ity (MD); FA is typically low and MD is high in brain damage in
MS as compared to normal controls.
Magnetic resonance spectroscopy (MRS) determines the
relative concentration of brain metabolites, whose levels alter
in the course of the disease. The main metabolites whose
levels can change in MS, are:
(1) Choline (Cho), which is the marker of axonal loss and
neuronal integrity, rising during inﬂammation and demyelin-
ation, (2) N-acetyloaspartate (NAA) – decreased since the ﬁrst
stages of MS, correlating with axonal damage, (3) lactates (Lac) –
increasing in the case of an energetic process breakdown and
reﬂecting myelin damage and necrosis, (4) mioinositol (mI),
which increases as a gliosis and inﬂammation marker. Recent
studies have demonstrated that mI elevation precedes brain
volume loss and NAA decreases in early stages of MS
[7,15,45,46].
5. Effects of already approved therapies on
brain atrophy
Each modern drug trial in MS includes 3D-T1 sequences in MRI
protocol. Atrophy is a marker of neurodegeneration and many
new drugs are thoroughly examined as to their effect on theslowing of brain volume decrease. In a meta-analysis by
Sormani et al., 13 trials comprising more than 13,500 patients
were assessed. The results describe a correlation between
atrophy and 2-year disability progression as factors inﬂuenced
by the treatment. Additionally, an analysis of atrophy decrease
adds a lot when assessed together with treatment effects on
active MRI lesions. When these factors are analysed in
combination, they explain better the reduction of disability
progression after initiating treatment. The authors conclude
that brain atrophy assessment is a highly valuable marker for
disability progression, both alone and in combination with
inﬂammatory markers [35].
6. Conclusions
It must be concluded that today we are not able to translate
directly the results of brain atrophy assessment into decisions
on the management of patients. However, this is the trend of
the latest publications and this parameter is assessed in
clinical trials in MS.
A universal access to the possibility of calculating the
volume parameters in routine MRI scan will become reality in
the near future. An assessment of brain atrophy with the use of
3D-T1 sequences may be implemented into daily practice.
Let us hope that the results of research on brain atrophy in
multiple sclerosis will contribute to progress in therapy, and
an assessment of atrophy by radiologists will be used
effectively in neurological practice.
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